Holen Sie sich die Stockscreener-App
31.47
0.00%
0.00
Schlusskurs vom Vortag:
$31.47
Offen:
$31.47
24-Stunden-Volumen:
1.35M
Relative Volume:
0.59
Marktkapitalisierung:
$3.85B
Einnahmen:
$596.96M
Nettoeinkommen (Verlust:
$221.32M
KGV:
18.09
EPS:
1.7397
Netto-Cashflow:
$208.13M
1W Leistung:
+0.06%
1M Leistung:
+0.41%
6M Leistung:
+38.51%
1J Leistung:
+44.03%
1-Tages-Spanne:
$31.47
$31.48
1-Wochen-Bereich:
$31.45
$31.50
52-Wochen-Spanne:
$19.05
$32.56
Catalyst Pharmaceuticals Inc Stock (CPRX) Company Profile
Firmenname
Catalyst Pharmaceuticals Inc
Sektor
Branche
Telefon
(305) 529-2522
Adresse
355 ALHAMBRA CIRCLE, CORAL GABLES
Compare CPRX vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CPRX
Catalyst Pharmaceuticals Inc
|
31.47 | 3.85B | 596.96M | 221.32M | 208.13M | 1.7397 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Catalyst Pharmaceuticals Inc Stock (CPRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-04 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-11-18 | Eingeleitet | Stephens | Overweight |
| 2024-03-14 | Eingeleitet | Citigroup | Buy |
| 2024-03-07 | Eingeleitet | BofA Securities | Buy |
| 2023-12-21 | Eingeleitet | Oppenheimer | Outperform |
| 2022-08-24 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2018-09-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-09-07 | Fortgesetzt | Piper Jaffray | Overweight |
| 2016-10-05 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2016-04-26 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2014-09-30 | Bestätigt | ROTH Capital | Buy |
| 2014-09-16 | Bestätigt | ROTH Capital | Buy |
| 2014-09-15 | Bestätigt | H.C. Wainwright | Buy |
| 2013-10-21 | Bestätigt | Aegis Capital | Buy |
| 2013-09-24 | Eingeleitet | Maxim Group | Buy |
| 2013-09-06 | Bestätigt | Aegis Capital | Buy |
| 2013-04-18 | Eingeleitet | Aegis Capital | Buy |
| 2012-08-27 | Hochstufung | Rodman & Renshaw | Mkt Perform → Mkt Outperform |
| 2009-10-01 | Hochstufung | Merriman | Sell → Neutral |
| 2009-05-29 | Herabstufung | Hapoalim | Neutral → Underperform |
| 2009-05-29 | Herabstufung | Merriman Curhan Ford | Buy → Sell |
| 2008-12-15 | Eingeleitet | Merriman Curhan Ford | Buy |
| 2007-11-28 | Eingeleitet | Rodman & Renshaw | Mkt Outperform |
| 2007-01-31 | Eingeleitet | Stifel Nicolaus | Buy |
| 2007-01-05 | Eingeleitet | First Albany | Buy |
Alle ansehen
Catalyst Pharmaceuticals Inc Aktie (CPRX) Neueste Nachrichten
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX): A Textbook GARP Stock Delivering Affordable Growth - ChartMill
Catalyst Pharmaceuticals Stockholders Clear Angelini Pharma Merger - Yahoo Finance
Solaris Energy replaces Catalyst Pharmaceuticals in S&P SmallCap 600 as acquisition nears completion - Pluang
Catalyst Pharmaceuticals (CPRX) Proxy filing Summary - Quartr
Catalyst Pharmaceuticals (CPRX) Q1 2025 earnings summary - Quartr
Catalyst (CPRX) up 0.6% since last earnings report: Can it continue? - MSN
Catalyst Pharmaceuticals (NASDAQ: CPRX) investors back Angelini Pharma merger deal - Stock Titan
Catalyst Pharmaceuticals (CPRX) EGM 2026 Summary - Quartr
Catalyst Pharmaceuticals focuses on rare neuromuscular diseases as a specialized Nasdaq biotech - ad-hoc-news.de
Catalyst Pharmaceuticals (CPRX) Stock Looks Fairly Valued After Phase 1 Agamree Data - Sahm
Angelini Pharma to acquire Catalyst Pharmaceuticals for $4.1bn - Investing.com
CPRX's Agamree Shows Potential Beyond DMD After Positive Phase I Data - The Globe and Mail
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX): A Deep Value Play with Rare Disease Pipeline Strength - ChartMill
CPRXCatalyst Pharmaceuticals Inc Earnings - Finviz
Santhera Notes Topline Results from Catalyst Pharmaceuticals’ Phase 1 Clinical Study of AGAMREE® - NTB Kommunikasjon
Vamorolone Phase 1 results at Catalyst (NASDAQ: CPRX) show activity without key immunosuppression - Stock Titan
Catalyst reports Phase 1 vamorolone study results - Investing.com
Vamorolone Demonstrates On-Target Glucocorticoid Activity Without the Immunosuppression Characteristic of Traditional Corticosteroids at Clinical Doses - The Manila Times
Catalyst reports Phase 1 vamorolone study results By Investing.com - Investing.com Canada
Vamorolone Demonstrates On-Target Glucocorticoid Activity - GlobeNewswire
Monolithic Power Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Monolithic Power Systems, Inc.MPWR - Business Wire
Skeletal Nickel Catalyst Market Growth to Accelerate by 2035 Amid Rising Pharma DemandNews and Statistics - IndexBox
Acadia Pharmaceuticals (ACAD) Gets 90-Day Catalyst Watch from Ci - GuruFocus
Quantified Common Ground Fund's Catalyst Pharmaceuticals Inc(CPRX) Holding History - GuruFocus
Catalyst Pharmaceuticals (CPRX) Following Strong Rare Disease Results Is The Upside Already Priced In - Sahm
Shuttle Pharmaceuticals (NASDAQ:SHPH) surges; Dogecoin miner news sends volume up 70x - TechStock²
Price to earnings forward of Catalyst Pharmaceuticals, Inc. – NASDAQ:CPRX - TradingView
Price to sales forward of Catalyst Pharmaceuticals, Inc. – NASDAQ:CPRX - TradingView
Enterprise value to revenue forward of Catalyst Pharmaceuticals, Inc. – NASDAQ:CPRX - TradingView
Price to book forward of Catalyst Pharmaceuticals, Inc. – NASDAQ:CPRX - TradingView
Enterprise value to EBIT forward of Catalyst Pharmaceuticals, Inc. – NASDAQ:CPRX - TradingView
Enterprise value to EBITDA forward of Catalyst Pharmaceuticals, Inc. – NASDAQ:CPRX - TradingView
Understanding the Setup: (CPRX) and Scalable Risk - Stock Traders Daily
Catalyst Pharmaceuticals (CPRX) Short Interest & Short Float | Updated Jun 2026 - MarketBeat
Nationwide Renaissance Small Cap Growth Fund's Catalyst Pharmaceuticals Inc(CPRX) Holding History - GuruFocus
Catalyst Pharmaceuticals stock edges higher to 31.41 after patient summit event, CatalystForRare - Traders Union
Catalyst Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Catalyst Pharmaceuticals, Inc.CPRX - Business Wire
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Passes "Caviar Cruise" Quality Screen with Zero Debt and 147.5% ROIC - ChartMill
Catalyst Pharmaceuticals (CPRX) Gets Early FTC Clearance For Angelini Merger - Sahm
Catalyst Pharmaceuticals to Be Acquired by Angelini Pharma in All-Cash Merger – Key Details from 8-K Filing - Minichart
Catalyst Pharma Gains FTC Clearance for Angelini Merger - TipRanks
Catalyst Pharmaceuticals merger cleared HSR waiting period as closing targets Q3 2026 - TradingView
HSR waiting period ends for Catalyst (NASDAQ: CPRX) and Angelini Pharma merger - Stock Titan
Catalyst Pharmaceuticals consensus steadies, Hold rating frames CPRX shares - AD HOC NEWS
Catalyst Pharmaceuticals Inc (CPRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Catalyst Pharmaceuticals Inc (CPRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Catalyst Pharmaceuticals Inc - TradingKey
Catalyst Pharmaceuticals Inc (CPRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
SMID Core Equity Portfolio's Catalyst Pharmaceuticals Inc(CPRX) Holding History - GuruFocus
Catalyst Pharmaceuticals Inc (CPRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Catalyst Pharmaceuticals Inc (CPRX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Finanzdaten der Catalyst Pharmaceuticals Inc-Aktie (CPRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.64%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):